Startup profile · funding coverage
General Medicine funding, valuation and investors
Consumer healthcare marketplace for comparing and buying medications, labs, telehealth and care services.
Keep track of General Medicine
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$120M · October 6, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$120M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Francisco, California, United States
Investors in latest funding
Lead: Andreessen Horowitz
Other: Matrix , VXI Capital , Eli Lilly and Company , Granger Management , BoxGroup
Overview
General Medicine operates a nationwide healthcare store in the United States with a catalog spanning medications, labs, telehealth, specialist e-consults and selected in-person services.
Why General Medicine is interesting
General Medicine is trying to package fragmented healthcare purchasing into a consumer-style catalog with upfront pricing both with and without insurance.
Funding history (newest first)
Series B
2026-10-06 $120M- Andreessen Horowitz (lead)
- Matrix (participant)
- VXI Capital (participant)
- Eli Lilly and Company (participant)
- Granger Management (participant)
- BoxGroup (participant)
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover General Medicine's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.